TrialBreast cancer research and treatment2020

A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.

J Watanabe et al.PubMed ↗Publisher ↗

No numbers read from the abstract.